Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Shares Outstanding (Weighted Average) (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $129.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 15.88% to $129.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.8 million through Dec 2025, up 15.88% year-over-year, with the annual reading at $129.8 million for FY2025, 15.88% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $129.8 million at TScan Therapeutics, roughly flat from $129.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $129.8 million in Q3 2025, with the low at $1.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $63.9 million, with a median of $50.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 1866.89% in 2022, then increased 1.05% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $11.7 million in 2021, then surged by 106.2% to $24.0 million in 2022, then surged by 172.78% to $65.6 million in 2023, then surged by 70.72% to $112.0 million in 2024, then rose by 15.88% to $129.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $129.8 million, $129.8 million, and $129.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.